Latus Bio has successfully raised $54 million in funding to continue its pioneering work in developing cutting-edge therapeutics for CNS disorders using revolutionary AAV capsids. The company, founded on the transformative research of Professor Beverly Davidson, is dedicated to leveraging targeted gene therapies to revolutionize patient care. Latus Bio's focus on diseases like CLN2 and Huntington’s disease underscores its commitment to reshaping the landscape of healthcare with innovative solutions that prioritize safety and efficacy. With a diverse team of experts and a robust pipeline, Latus Bio is on track to advance towards clinical trials by late 2025, marking a significant step in the journey to redefine the treatment of complex neurological conditions. Join Latus Bio in its mission to harness the power of gene therapy and make a meaningful impact on the lives of individuals globally. Visit www.latusbio.com and follow the company on LinkedIn to stay updated on its groundbreaking progress.
Latus Bio Secures $54M in Series A Funding to Revolutionize Gene Therapy for CNS Disorders
Recently funded · $54.0M Series aBiotechnology Research
Get the full Latus Bio company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Aisot Technologies
Aisot Technologies is a Zurich-based AI company pioneering advanced, AI-driven investment solutions. Spun out of ETH Zurich in 2021, aisot leverages machine learning, large language models (LLMs), and quantitative methods to deliver precise, real-time investment insights. Its AI Insights Platform empowers asset managers, funds, family offices, and treasuries to anticipate market trends, optimize strategies, and mitigate risk. Recognized across Europe and the U.S., aisot partners with leading financial institutions to redefine quantitative investment management.
$2.5M Seed
today
Dognosis
Dognosis is a deep-tech startup in Bangalore decoding canine cognition to reveal the hidden world of scent. Our vision is a world where we have cracked the olfactory code of disease, making detecting disease as easy as breathing. Our mission is to save lives by detecting disease early and advance humanity towards truly proactive and preventative medicine. Our work revolves around increasing the bandwidth of human-canine collaboration, allowing us to catch the scent of disease at scale. Our first goal is to solve for early cancer detection by pioneering a multi-cancer breath-based test - BreathEasy - that will be ultra-affordable, highly accurate, and super accessible. We're always on the lookout for passionate and ambitious people to work with us. Feel free to say hi to woof@dognosis.tech
Other recent Series a rounds
Companies that recently closed a Series a round.
| # | Company | Round | Amount | Date |
|---|---|---|---|---|
| 1 |  Aligned Marketplace | Series a | $20.0M | today |
| 2 |  Vals AI United States | Series a | $40.0M | today |
| 3 |
.png&w=3840&q=75)